Baltic Post-Marketing Study of Pegilated Interferon Α-2a 40 KD Efficacy and Safety in Patients With HBeAg–Positive and HBeAg – Negative Chronic Hepatitis B
Virology & Mycology
doi 10.4172/2161-0517.1000108
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2013
Authors
Publisher
OMICS Publishing Group